Tumour suppression induced by the macrophage activating lipopeptide MALP-2 in an ultrasound guided pancreatic carcinoma mouse model

Schneider, C.; Schmidt, T.; Ziske, C.; Tiemann, K.; Lee, K-M.; Uhlinsky, V.; Behrens, P.; Sauerbruch, T.; Schmidt-Wolf, I. G. H.; Mühlradt, P. F.; Schmidt, J.; Märten, A.
March 2004
Gut;Mar2004, Vol. 53 Issue 3, p355
Academic Journal
Background and aim: Carcinoma of the exocrine pancreas has a particularly poor prognosis. Therefore, novel therapeutic strategies such as immunotherapy are required. Here we investigated the immunomodulatory capacity of macrophage activating lipopeptide 2 (MALP-2), which binds to toll-like receptors 2 and 6 and induces activation of nuclear factor κB in monocytes. This causes the release of early stage leucocyte attracting chemokines and proinflammatory cytokines. Methods: MALP-2 was tested in a new orthotopic ultrasound guided pancreatic cancer mouse model. This model is close to the biological situation and avoids the stress and immunostimulation caused by laparotomy. Cells from the syngeneic, highly aggressive, and metastatic cell line Panc 02 were administered orthotopically, by ultrasound guidance, to C57bl/6 mice. MALP-2 was administered intratumorally or intraperitoneally and tumour growth, immune status, and leucocyte infiltration at the tumour site were determined. Results: We showed a tumour suppressive effect induced by a single injection of MALP-2. Median survival increased from 21 to 30 days (p<0.002). Combining chemotherapy (gemcitabine) with MALP-2 treatment caused further prolonged survival (median survival 27 days with chemotherapy alone v 37 days for combined treatment; p<0.0002). The life prolonging effect was paralleled by a significant increase in cytotoxic T cells, restoration of β2 integrin expression on lymphocytes, and high expression of CD45RB on T helper cells. Immunohistochemical stains showed strong cytotoxic T lymphocyte and natural killer cell infiltration. Conclusions: In conclusion, in a model of orthotopic pancreatic cancer in mice, we induced a tumour suppressive effect by treatment with a synthetic lipopeptide. Treatment with MALP-2 could be an option for immunotherapy in pancreatic cancer.


Related Articles

  • CD40 immunotherapy for pancreatic cancer. Vonderheide, Robert; Bajor, David; Winograd, Rafael; Evans, Rebecca; Bayne, Lauren; Beatty, Gregory // Cancer Immunology, Immunotherapy;May2013, Vol. 62 Issue 5, p949 

    Pancreatic ductal adenocarcinoma (PDA) is a highly aggressive and lethal cancer which is poorly responsive to standard therapies. Although the PDA tumor microenvironment is considered especially immunosuppressive, recent data mostly from genetically engineered and other mouse models of the...

  • Using macrophage activation to augment immunotherapy of established tumours. Fridlender, Z G; Jassar, A; Mishalian, I; Wang, L-CS; Kapoor, V; Cheng, G; Sun, J; Singhal, S; Levy, L; Albelda, S M // British Journal of Cancer;4/2/2013, Vol. 108 Issue 6, p1288 

    Background:Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting tumour microenvironment. We hypothesised that altering TAM phenotype would augment the efficacy of...

  • Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. Cao, Zhu Alexander; Daniel, Dylan; Hanahan, Douglas // BMC Cancer;2002, Vol. 2, p11 

    Background: It is not uncommon to observe circulating tumor antigen-specific T lymphocytes in cancer patients despite a lack of significant infiltration and destruction of their tumors. Thus, an important goal for tumor immunotherapy is to identify ways to modulate in vivo anti-tumor immunity to...

  • Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Ino, Y; Yamazaki-Itoh, R; Shimada, K; Iwasaki, M; Kosuge, T; Kanai, Y; Hiraoka, N // British Journal of Cancer;3/5/2013, Vol. 108 Issue 4, p914 

    Background:The host immune reaction is represented by immune/inflammatory cell infiltrates. Here we systematically analysed tumour-infiltrating immune/inflammatory cells in pancreatic ductal carcinoma (PDC) and evaluated their clinicopathological impact.Methods:Using immunohistochemistry, we...

  • Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists. Luheshi, Nadia; Davies, Gareth; Legg, James // OncoImmunology;Feb2014, Vol. 3 Issue 2, pN.PAG 

    Both TH1 and TH2 cytokines influence the antitumor functions of macrophages. We have recently shown that interferon ? (IFN?) licenses the antineoplastic functions of CD40 ligand (CD40L)-stimulated macrophages more efficiently than interleukin (IL)-4 and IL-13. The presence of a TH1 and TH2...

  • Rationalisation of cancer therapy: modelling the physical and immunological tumour microenvironment. Kok-Ho Ho // Australian Medical Student Journal;Jul2013, Vol. 4 Issue 1, p21 

    The tumour microenvironment has emerged as an important field in carcinogenesis. For most of the 20th century, cancer therapies have focused predominantly on tumour cells. Despite our best efforts, these therapies remain ineffective against cancers with poor prognosis such as ovarian and...

  • Clinical importance of B7-H3 expression in human pancreatic cancer. Yamato, I.; Sho, M.; Nomi, T.; Akahori, T.; Shimada, K.; Hotta, K.; Kanehiro, H.; Konishi, N.; Yagita, H.; Nakajima, Y. // British Journal of Cancer;11/17/2009, Vol. 101 Issue 10, p1709 

    Background:B7-H3 is a new member of the B7 ligand family and regulates T-cell responses in various conditions. However, the role of B7-H3 in tumour immunity is largely unknown. The purpose of this study was to evaluate the clinical significance of B7-H3 expression in human pancreatic cancer and...

  • Pancreatic Perivascular Epithelioid Cell Tumour Presenting with Upper Gastrointestinal Bleeding. Petrides, Christos; Neofytou, Kyriakos; Khan, Aamir Z. // Case Reports in Oncological Medicine;1/6/2015, Vol. 2015, p1 

    PEComa is a family of rare mesenchymal tumours which can occur in any part of the human body. Primary PEComas of the pancreas are extremely rare tumours with uncertain malignant potential. A 17-year-old female was admitted to the hospital due to melena. She required several transfusions. CT scan...

  • Vitamin D-binding protein-derived macrophage-activating factor, GcMAF, and prostate cancer. Bellone, Matteo; Rigamonti, Nicolò // Cancer Immunology, Immunotherapy;Dec2012, Vol. 61 Issue 12, p2377 

    No abstract available.


Read the Article


Sign out of this library

Other Topics